GE Healthcare Technologies Inc (GEHC) AI Stock Analysis

• Market Cap: $37.95B
• Dividend Yield: 0.17%
• Average Volume (3M): 3.76M
• Price to Earnings (P/E): 17.2
• Beta (1Y): 1.24
• Revenue Growth: 3.52%
• EPS Growth: 32.21%
• Country: US
• Employees: 53,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 1.07
• Shares Outstanding: 455,521,600
• 10 Day Avg. Volume: 3,119,097
• 30 Day Avg. Volume: 3,762,340
• PEG Ratio: 0.41
• Price to Book (P/B): 4.22
• Price to Sales (P/S): 1.81
• P/FCF Ratio: 23.00
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 2.02
• Enterprise Value/Gross Profit: 4.96
• Enterprise Value/Ebitda: 10.79
• 1Y Price Target: $89.75
• Price Target Upside: 7.72% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): 4.55
• Revenue Forecast (FY): $20.54B

• Rating: 78 Outperform
• Price Target: $94.00 ▲(12.82% Upside)

GE Healthcare Technologies Inc. demonstrates strong financial performance and technical momentum, supported by strategic earnings call insights. While valuation is fair, liquidity challenges and tariff impacts are notable risks. The company's strategic initiatives and raised EPS guidance provide a positive outlook.

Positive Factors

Strategic Partnerships

Long-term partnerships enhance GEHC's product portfolio and market reach, driving sustainable growth through collaborative innovation.

Revenue Growth

Consistent revenue growth indicates strong market demand and effective business strategies, supporting long-term financial health.

Regulatory Approvals

Securing regulatory approvals for new technologies strengthens GEHC's competitive position and expands its product offerings.

Negative Factors

Cash Flow Challenges

Declining cash flow can strain liquidity and limit investment capacity, potentially impacting long-term operational flexibility.

Tariff Impacts

Tariff impacts on margins highlight vulnerability to external economic factors, potentially affecting profitability and cost management.

Patient Care Solutions Segment

Challenges in this segment could indicate operational issues or market shifts, affecting overall business performance and growth potential.

GE Healthcare Technologies Inc Business Overview & Revenue Model

Company Description

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

How the Company Makes Money

GE Healthcare generates revenue through several key streams, primarily from the sale of medical imaging equipment, monitoring devices, and software solutions. The company also earns income from service contracts related to the maintenance and support of its products, as well as consumables and accessories that accompany its medical devices. Additionally, GEHC has established significant partnerships with healthcare providers, research institutions, and technology firms, which contribute to its revenue through collaborative projects and the development of innovative healthcare solutions. The ongoing demand for advanced medical technologies, particularly in emerging markets and during healthcare transformations, also plays a crucial role in driving GEHC's earnings.

GE Healthcare Technologies Inc Financial Statement Overview

Summary

GE Healthcare Technologies Inc. shows strong revenue growth and profitability, with significant improvements in leverage and return on equity. However, challenges in cash flow generation could impact liquidity, necessitating a focus on cost management and cash flow improvement.

Income Statement

GE Healthcare Technologies Inc. demonstrates strong revenue growth with a TTM increase of 1.4%, indicating a positive trajectory. The company maintains healthy profitability with a gross profit margin of 40.8% and a net profit margin of 10.9% in the TTM. EBIT and EBITDA margins are also robust at 15.9% and 18.8% respectively, reflecting efficient operations. However, the slight decline in gross profit margin from the previous year suggests potential cost pressures.

Balance Sheet

The balance sheet shows a significant improvement in leverage, with a TTM debt-to-equity ratio of 0.20, down from 1.11 the previous year, indicating reduced financial risk. The return on equity remains strong at 23.7%, showcasing effective use of equity. However, the equity ratio is not explicitly calculated, and the decrease in stockholders' equity over the years could be a concern for long-term stability.

Cash Flow

Cash flow analysis reveals challenges with a significant decline in free cash flow growth by 70.4% in the TTM, indicating potential liquidity issues. The operating cash flow to net income ratio is low at 0.09, suggesting that cash generation from operations is not keeping pace with net income. However, the free cash flow to net income ratio remains healthy at 50.7%, indicating some level of cash flow efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.25B	19.67B	19.55B	18.34B	17.59B	17.16B
Gross Profit	8.26B	8.21B	7.92B	7.18B	7.17B	6.77B
EBITDA	3.80B	3.67B	3.51B	3.17B	3.54B	3.41B
Net Income	2.22B	1.99B	1.57B	1.92B	2.25B	13.85B
Balance Sheet
Total Assets	36.13B	33.09B	32.45B	27.54B	26.31B	24.23B
Cash, Cash Equivalents and Short-Term Investments	4.00B	2.89B	2.50B	1.45B	556.00M	1.01B
Total Debt	10.74B	9.38B	9.86B	8.63B	437.00M	468.00M
Total Liabilities	25.91B	24.44B	25.14B	17.95B	9.41B	9.25B
Stockholders Equity	9.99B	8.45B	7.13B	9.36B	16.66B	14.73B
Cash Flow
Free Cash Flow	1.40B	1.55B	1.71B	1.80B	1.36B	1.43B
Operating Cash Flow	1.85B	1.95B	2.10B	2.11B	1.61B	1.69B
Investing Cash Flow	-1.02B	-914.00M	-558.00M	-398.00M	-1.76B	19.99B
Financing Cash Flow	-367.00M	-573.00M	-478.00M	-822.00M	-263.00M	-21.54B

GE Healthcare Technologies Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 83.32
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GEHC, the sentiment is Positive. The current price of 83.32 is above the 20-day moving average (MA) of 82.70, above the 50-day MA of 77.98, and above the 200-day MA of 74.41, indicating a bullish trend. The MACD of 1.70 indicates Positive momentum. The RSI at 57.48 is Neutral, neither overbought nor oversold. The STOCH value of 36.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GEHC.

GE Healthcare Technologies Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GEHC	78 Outperform	$37.95B	17.23	24.22%	0.17%	3.52%	32.21%
HQY	76 Outperform	$7.92B	42.48	9.01%	―	12.20%	98.75%
DOCS	72 Outperform	$8.20B	34.72	24.61%	―	20.21%	44.14%
HNGE	70 Outperform	$3.84B	-8.88	―	―	50.67%	-578.00%
VEEV	66 Neutral	$36.86B	43.58	13.72%	―	15.96%	27.91%
TEM	52 Neutral	$11.51B	―	-72.61%	―	72.58%	76.81%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

GE Healthcare Technologies Inc Corporate Events

GE Healthcare Issues $1.25 Billion in Senior Notes

On December 12, 2025, GE Healthcare Technologies Inc. entered into a three-year senior unsecured term loan credit facility for $750 million, with JPMorgan Chase Bank as the administrative agent. This agreement includes various covenants and is aimed at supporting the company’s financial operations. Additionally, on December 15, 2025, GE Healthcare issued $1.25 billion in senior notes to finance its acquisition of Intelerad Medical Systems, marking a strategic expansion in its healthcare solutions portfolio. The notes are set to mature in 2028 and 2035, respectively, and are part of the company’s broader financial strategy to enhance its market positioning.

GE Healthcare Announces $1.25 Billion Notes Offering

On December 1, 2025, GE Healthcare Technologies Inc. announced the commencement and pricing of an underwritten offering of $1.25 billion in aggregate principal amount of notes, with $600 million due in 2028 and $650 million due in 2035. This financial move, involving major underwriters like Goldman Sachs and BNP Paribas, is expected to impact the company’s financial strategy and market positioning, with the notes anticipated to be issued around December 15, 2025, pending customary closing conditions.